Bruker (NASDAQ:BRKR) Posts Earnings Results, Beats Expectations By $0.14 EPS

Bruker (NASDAQ:BRKR) issued its quarterly earnings results on Wednesday. The medical research company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.42 by $0.14, FiscalAI reports. Bruker had a positive return on equity of 13.76% and a negative net margin of 3.82%. The firm had revenue of $874.00 million during the quarter, compared to analysts’ expectations of $865.16 million. During the same period in the previous year, the business earned $0.45 earnings per share. The firm’s revenue for the quarter was up 1.6% on a year-over-year basis.

Here are the key takeaways from Bruker’s conference call:

• Margins and adjusted EPS improved sharply: Q3 non-GAAP operating margin rose 400 basis points to 16.3%, and diluted non-GAAP EPS increased 24% to $0.56, helped by cost savings and favorable product mix.
• Bookings point to improving demand: BSI book-to-bill remained above one for a fifth consecutive quarter, with year-to-date bookings and backlog up mid-single digits. Management cited strong China demand, a return to U.S. academic and government bookings growth, and more than 30% year-to-date growth in semiconductor metrology orders.
• Bruker reaffirmed its 2026 organic revenue growth outlook of 1%–2% and non-GAAP EPS range of $2.10–$2.15; it expects lower-mid-single-digit organic revenue growth in Q4. Management said 2027 should bring faster organic growth, further margin expansion, and double-digit EPS growth, while noting detailed guidance will come in February.
• Reported growth remained modest: Q3 organic revenue increased just 0.7%, while BSI organic revenue declined 0.4%, partly due to previously disclosed semiconductor instrument pushouts. GAAP results included a roughly $175 million non-cash goodwill impairment tied to Bruker Spatial Biology and a diluted loss per share of $0.81.

Bruker Trading Down 9.0%

Shares of Bruker stock opened at $58.06 on Friday. The firm has a market capitalization of $8.85 billion, a price-to-earnings ratio of -52.78, a PEG ratio of 1.95 and a beta of 1.26. Bruker has a fifty-two week low of $32.37 and a fifty-two week high of $68.98. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.92 and a current ratio of 1.84. The stock has a 50 day moving average of $58.97 and a 200 day moving average of $50.53.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Monday, September 21st were given a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date was Monday, September 21st. Bruker’s dividend payout ratio is presently -28.57%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on BRKR shares. Zacks Research cut shares of Bruker from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 2nd. Citigroup increased their price objective on shares of Bruker from $53.00 to $64.00 and gave the company a “neutral” rating in a report on Thursday. The Goldman Sachs Group upgraded Bruker from a “strong sell” rating to a “strong-buy” rating in a report on Monday, September 21st. Barclays lifted their price objective on Bruker from $58.00 to $70.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Finally, TD Cowen upped their target price on Bruker from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 13th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $60.57.

Insider Buying and Selling

In other Bruker news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total value of $105,740.00. Following the sale, the vice president owned 134,806 shares in the company, valued at $7,127,193.22. The trade was a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 27.20% of the stock is owned by corporate insiders.

Bruker Company Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.